Journal of Breast Cancer最新文献

{"title":"Somatic Mutations in Breast Cancer: The Tip of the Iceberg.","authors":"Jung Ho Park, Lee Su Kim","doi":"10.4048/jbc.2022.25.e52","DOIUrl":"https://doi.org/10.4048/jbc.2022.25.e52","url":null,"abstract":"Mutations of","PeriodicalId":15206,"journal":{"name":"Journal of Breast Cancer","volume":"25 6","pages":"523-524"},"PeriodicalIF":2.4,"publicationDate":"2022-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/28/1e/jbc-25-523.PMC9807321.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9077893","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Somatic Mutations of <i>TP53</i> and Prognostic Factors for Primary Operable Breast Cancer: Correspondence.","authors":"Pathum Sookaromdee,&nbsp;Viroj Wiwanitkit","doi":"10.4048/jbc.2022.25.e51","DOIUrl":"https://doi.org/10.4048/jbc.2022.25.e51","url":null,"abstract":"de Groot S, Baak-Pablo R, Kranenbarg EM, Seynaeve CM, van de Velde CJ, et al. The variant T allele of PvuII in ESR1 gene is a prognostic marker in early breast cancer survival. Sci Rep 2021;11:3249. PUBMED | CROSSREF","PeriodicalId":15206,"journal":{"name":"Journal of Breast Cancer","volume":"25 6","pages":"522"},"PeriodicalIF":2.4,"publicationDate":"2022-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/95/c9/jbc-25-522.PMC9807318.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9077890","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Bisphosphonates and Prevention of the Perimenopausal Breast Cancer Recurrence: A Systematic Review and Meta-Analysis.","authors":"Zohreh Sanaat,&nbsp;Ozra Nouri,&nbsp;Monireh Khanzadeh,&nbsp;Hadi Mostafaei,&nbsp;Nafiseh Vahed,&nbsp;Neda Kabiri,&nbsp;Reza Ali Akbari Khoei,&nbsp;Hanieh Salehi-Pourmehr","doi":"10.4048/jbc.2022.25.e39","DOIUrl":"https://doi.org/10.4048/jbc.2022.25.e39","url":null,"abstract":"<p><strong>Purpose: </strong>Bisphosphonates (BPs) have a powerful effect on reducing bone resorption and improving the survival of patients with breast cancer. We aimed to investigate the impact of BP treatment on the prevention of recurrence, metastasis, and death of breast cancer survivors in the perimenopausal period.</p><p><strong>Methods: </strong>The search strategy aimed to identify both published and unpublished studies in PubMed, Web of Science, Scopus, Embase, ProQuest, and Google Scholar in March 2021. Two independent reviewers assessed quantitative papers selected for retrieval for methodological validity before being included in the review using standardized critical appraisal instruments from the Joanna Briggs Institute (JBI) Meta-Analysis of Statistics Assessment and Review Instrument (JBI-MAStARI). Statistical meta-analysis was performed using Review Manager (RevMan) 5.4 statistical software when the data were homogenous. Meta-analysis was performed by calculating the effect size (hazard ratio; HR) and 95% confidence intervals (CIs).</p><p><strong>Results: </strong>Twenty-one studies were eligible for this systematic review and meta-analysis. The overall The HRs for disease-free survival (DFS) and overall survival (OS) in women who received BPs were 0.89 (95% CI, 0.83-0.97; <i>p</i> = 0.005), and 0.75 (95% CI, 0.63-0.89; <i>p</i> = 0.001), respectively. The results showed that BPs had a significant effect on the prevention of locoregional (HR, 0.64; 95% CI, 0.42-0.97; <i>p</i> = 0.04), bone (95% CI, 0.74-0.95; <i>p</i> ≤ 0.001), and distant metastases (HR, 0.77; 95% CI, 0.62-0.94; <i>p</i> = 0.01). In the subgroup analysis based on study design, the only insignificant HR in the included randomized controlled trials (RCTs) was that of locoregional metastasis.</p><p><strong>Conclusion: </strong>Although BPs have a promising effect on DFS, OS, and bone metastasis of perimenopausal women survivors of breast cancer, more RCTs are needed to evaluate their effect on other survivors' outcomes.</p>","PeriodicalId":15206,"journal":{"name":"Journal of Breast Cancer","volume":"25 6","pages":"454-472"},"PeriodicalIF":2.4,"publicationDate":"2022-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/dd/72/jbc-25-454.PMC9807326.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10512664","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Corrigendum: Increased Melanoma-Associated Antigen C2 Expression Affords Resistance to Apoptotic Deathin Suspension-Cultured Tumor Cells.","authors":"Doyeon Park,&nbsp;Sora Han,&nbsp;Hyunjeong Joo,&nbsp;Hye In Ka,&nbsp;Sujung Soh,&nbsp;Jiyoung Park,&nbsp;Young Yang","doi":"10.4048/jbc.2022.25.e48","DOIUrl":"https://doi.org/10.4048/jbc.2022.25.e48","url":null,"abstract":"<p><p>This corrects the article on p. 138 in vol. 24, PMID: 33818016.</p>","PeriodicalId":15206,"journal":{"name":"Journal of Breast Cancer","volume":"25 6","pages":"525"},"PeriodicalIF":2.4,"publicationDate":"2022-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/df/1a/jbc-25-525.PMC9807323.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10863225","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prognostic Value of Neutrophil-to-Lymphocyte Ratio and Early Standardized Uptake Value Reduction in Patients With Breast Cancer Receiving Neoadjuvant Chemotherapy.","authors":"Soong June Bae,&nbsp;Sung Gwe Ahn,&nbsp;Jung Hwan Ji,&nbsp;Chih Hao Chu,&nbsp;Dooreh Kim,&nbsp;Janghee Lee,&nbsp;Soeun Park,&nbsp;Chihwan Cha,&nbsp;Joon Jeong","doi":"10.4048/jbc.2022.25.e44","DOIUrl":"https://doi.org/10.4048/jbc.2022.25.e44","url":null,"abstract":"<p><strong>Purpose: </strong>We investigated the treatment response and prognosis using the neutrophil-to-lymphocyte ratio (NLR) and standardized uptake value (SUV) of ¹⁸F-fluorodeoxyglucose positron emission tomography (¹⁸F-FDG PET) in neoadjuvant settings.</p><p><strong>Methods: </strong>Baseline NLR and maximum SUV (SUV_max) were retrospectively analyzed in 273 females with breast cancer who received neoadjuvant chemotherapy followed by surgery. Of these, 101 patients underwent ¹⁸F-FDG PET after 3-4 neoadjuvant chemotherapy cycles, which allowed the measurement of ΔSUV_max, an early reduction in SUV_max. NLR and early SUV_max reduction (ΔSUV_max) were classified as low and high, respectively, relative to the median values.</p><p><strong>Results: </strong>The mean NLR was lower, and the mean ΔSUV_max was higher in patients with pathologic complete response (pCR) than in those with residual tumors. The ΔSUV_max was an independent variable associated with pCR. Furthermore, the high NLR group had poor recurrence-free survival (RFS) and overall survival. Among patients with ΔSUV_max data, high NLR (adjusted hazard ratio, 2.82; 95% confidence intervals [CI], 1.26-6.28; <i>P</i> = 0.016) and low ΔSUV_max (adjusted hazard ratio, 2.39; 95% CI, 1.07-5.34; <i>P</i> = 0.037) were independent prognostic factors for poor RFS. The categorization of the patients into four groups according to the combination of NLR and ΔSUV_max showed that patients with high NLR and low ΔSUV_max had significantly poorer RFS.</p><p><strong>Conclusion: </strong>Baseline NLR and ΔSUV_max were significantly associated with the prognosis of patients with breast cancer who received neoadjuvant chemotherapy. These results suggest that metabolic non-responders with defective immune systems have worse survival outcomes.</p>","PeriodicalId":15206,"journal":{"name":"Journal of Breast Cancer","volume":"25 6","pages":"485-499"},"PeriodicalIF":2.4,"publicationDate":"2022-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/b5/53/jbc-25-485.PMC9807322.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10863223","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Somatic Mutations of <i>TP53</i> Identified by Targeted Next-Generation Sequencing Are Poor Prognostic Factors for Primary Operable Breast Cancer: A Single-Center Study.","authors":"Jung Ho Park,&nbsp;Mi Jung Kwon,&nbsp;Jinwon Seo,&nbsp;Ho Young Kim,&nbsp;Soo Kee Min,&nbsp;Lee Su Kim","doi":"10.4048/jbc.2022.25.e41","DOIUrl":"https://doi.org/10.4048/jbc.2022.25.e41","url":null,"abstract":"<p><p>Few studies have reported on the clinical utility of targeted next-generation sequencing (NGS) for breast cancer in Korea. We retrospectively reviewed the targeted NGS data of 219 patients with breast cancer who underwent surgical resection between August 2018 and April 2021. Here, we described the mutational profiles of breast cancer and examined their prognostic implications. The most frequently mutated gene was <i>PIK3CA</i> (n = 97/219, 44.3%), followed by <i>TP53</i> (n = 79/219, 36.1%), <i>AKT1</i> (n = 23/219, 10.5%), and <i>GATA3</i> (n = 20/219, 9.1%). <i>TP53</i> mutations were associated with aggressive histologic features. We followed up for 31 (range, 1-39) months and observed 11 (5.0%) recurrences: nine were <i>TP53</i> mutant and two were <i>TP53</i> wild-type. Multivariable analysis revealed that <i>TP53</i> mutation was an independent prognostic factor for recurrence (<i>p</i> = 0.012). Although no drug is currently available for <i>TP53</i> mutations, it is valuable to know the mutational status of <i>TP53</i> for the precise management of breast cancer.</p>","PeriodicalId":15206,"journal":{"name":"Journal of Breast Cancer","volume":"25 5","pages":"379-386"},"PeriodicalIF":2.4,"publicationDate":"2022-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/d3/f9/jbc-25-379.PMC9629967.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10448057","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Breast Magnetic Resonance Imaging for Patients With Newly Diagnosed Breast Cancer: A Review.","authors":"Soo-Yeon Kim,&nbsp;Nariya Cho","doi":"10.4048/jbc.2022.25.e35","DOIUrl":"https://doi.org/10.4048/jbc.2022.25.e35","url":null,"abstract":"<p><p>Despite the high sensitivity and widespread use of preoperative magnetic resonance imaging (MRI), the American Cancer Society and the National Comprehensive Cancer Network guidelines do not recommend the routine use of preoperative MRI owing to the conflicting results and lack of clear benefit to the surgical outcome (reoperation and mastectomy) and long-term clinical outcomes (local recurrence and metachronous contralateral breast cancer). Preoperative MRI detects additional cancers that are occult at mammography and ultrasound but increases the rate of mastectomy. Concerns about overdiagnosis and overtreatment of preoperative MRI might be mitigated by adjusting the confounding factors when conducting studies, using the state-of-the-art image-guided biopsy technique, applying the radiologists' cumulative experiences in interpreting MRI findings, and performing multiple lumpectomies in patients with multicentric cancer. Among the various imaging methods, dynamic contrast-enhanced MRI has the highest accuracy in predicting pathologic complete response after neoadjuvant chemotherapy. Prospective trials aimed at applying the MRI information to the de-escalation of surgical or radiation treatments are underway. In this review, current studies on the clinical outcomes of preoperative breast MRI are updated, and circumstances in which MRI may be useful for surgical planning are discussed.</p>","PeriodicalId":15206,"journal":{"name":"Journal of Breast Cancer","volume":"25 4","pages":"263-277"},"PeriodicalIF":2.4,"publicationDate":"2022-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/82/aa/jbc-25-263.PMC9411024.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9547715","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Association Between Smoking Status and Breast Cancer Recurrence: A Systematic Review","authors":"Muna Alkhaifi, Adam Clayton, T. Kishibe, J. Simpson","doi":"10.4048/jbc.2022.25.e23","DOIUrl":"https://doi.org/10.4048/jbc.2022.25.e23","url":null,"abstract":"Purpose To determine whether smoking status (active/passive) affects recurrence events after breast cancer (BC) diagnosis among women. Methods A comprehensive literature search of MEDLINE, Cochrane Central, EMBASE, and Web of Science databases on smoking status and BC outcomes retrieved 5,940 articles. After reviewing the inclusion and exclusion criteria, we selected 14 articles for a full review and synthesis. Results Five studies were cohort retrospective, 6 were case-control, 2 were prospective cohort studies, and 1 was a secondary analysis of a randomized control trial. Among the 8 articles that focused on active smoking, 6 showed an increased risk of BC recurrence, and 2 showed no evidence of such an association. Studies that examined former smokers found little evidence of an increased risk of BC recurrence. This association may be dose-dependent. Conclusion Given the current evidence, although limited, active smokers should quit smoking after BC diagnosis as trends indicate a positive association between active smoking and BC recurrence. More robust evidence is needed to assess such associations and examine the outcomes of quitting smoking in such patients.","PeriodicalId":15206,"journal":{"name":"Journal of Breast Cancer","volume":"25 1","pages":"278 - 287"},"PeriodicalIF":2.4,"publicationDate":"2022-05-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"42005408","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Optimal Timing of Imaging Examinations in Patients With Newly Diagnosed Breast Cancer in the COVID-19 Pandemic Era","authors":"J. Chang, S. Ha","doi":"10.4048/jbc.2022.25.e22","DOIUrl":"https://doi.org/10.4048/jbc.2022.25.e22","url":null,"abstract":"Our study was a retrospective study of patients with newly diagnosed breast cancer, who received concurrent coronavirus disease 2019 (COVID-19) vaccination in the ipsilateral arm, and underwent biopsy or surgery for axillary lymph nodes between April 2021 and September 2021. In our study population, the median interval between the most recent vaccination and imaging assessment was 26 days (range, 4–49 days) [1]. Previous reports have indicated that lymphadenopathy can develop as early as one day after the first dose, and is most likely to be seen within 14 days. However, the time to resolution of COVID-19 vaccine-associated lymphadenopathy varies, with persistent axillary lymphadenopathy observed up to 43 weeks post-vaccination [3]. In addition, patient and vaccine factors such as younger age, first dose, and mRNA vaccine type induce a higher incidence of axillary lymphadenopathy [4].","PeriodicalId":15206,"journal":{"name":"Journal of Breast Cancer","volume":"25 1","pages":"260 - 261"},"PeriodicalIF":2.4,"publicationDate":"2022-05-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"47384219","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Disparities in Access to Systemic Treatment for Breast Cancer in Thailand and Major Asian Territories","authors":"S. Ithimakin, N. Parinyanitikul, Sung-Bae Kim, Y. Yap, J. Tsang, I. Soong, Y. Ozaki, S. Ohno, M. Ono, Jack Junjie Chan, Hung-Chun Cheng, T. Dejthevaporn","doi":"10.4048/jbc.2022.25.e21","DOIUrl":"https://doi.org/10.4048/jbc.2022.25.e21","url":null,"abstract":"Purpose Breast cancer (BC) treatment has shifted from chemotherapy to targeted therapy. Several targeted agents have demonstrated an improvement in survival. Given that national healthcare resources were correlated with the cancer mortality-to-incidence ratio, we compared access to BC drugs in Thailand with that in other Asian countries. Methods BC experts involved in the Breast International Group (BIG)-Asia in six representative groups for countries or special administrative region (SAR) in Asia (Hong Kong SAR, Japan, Korea, Taiwan, Thailand, and Singapore) were invited to participate in the survey. The questionnaire addressed national health reimbursement schemes, molecular testing for early BC (EBC), availability and accessibility of BC drugs. Accessibility and reimbursement of the drugs were reported based on their listing as essential medicines in the World Health Organization Model List of Essential Medicines (WHO-EML) and their nomination as effective drugs in the European Society for Medical Oncology-Magnitude of Clinical Benefit Scale (ESMO-MCBS). The study was approved by all participating BIG-Asia organizations in November 2021. Results Genomic tests for EBC were non-reimbursable in all surveyed territories. Reimbursement and co-payment of BC drugs vary between and within these regions (particularly Thailand). Most drugs in the WHO-EML and ESMO-MCBS (A/B for EBC and 4/5 for advanced BC) were accessible in all surveyed territories. However, the accessibility of effective but costly WHO-EML and ESMO-MCBS drugs was not uniform in Thailand. There was an evident disparity for individuals covered by the Thai Social Security/Universal Health Coverage schemes. Conclusion Essential BC drugs are generally accessible in selected BIG-Asia countries or SAR. There is a disparity in accessing high-cost drugs in Thailand compared with other Asian territories.","PeriodicalId":15206,"journal":{"name":"Journal of Breast Cancer","volume":"25 1","pages":"207 - 217"},"PeriodicalIF":2.4,"publicationDate":"2022-05-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"48048044","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}